By now, you must have heard that hand washing, social distancing, wearing face masks and using a hand sanitizer are valuable tools in the fight against SARS-Cov-2 infection. It now turns out that using a dental mouthwash could also be an additional way to prevent the replication of the coronavirus once it gets into your mouth and throat.
Before you dismiss this suggestion as a wild idea, consider the fact that it was made by none other than the widely respected American Physiological Society. This society was established in 1887 and it brings together all biomedical professionals whose specialty is studying how cells, molecules, tissues and organs function in relation to health and disease. The group publishes 16 peer-reviewed journals whose readership is spread out across the globe.
In their recent evidence review article which appeared in the journal Function, the APS suggests that readily available dental mouthwashes have the capacity to destroy the lipid envelop of different coronaviruses. This destruction would prevent those viruses from replicating in the mouth and throat, thereby averting a likely infection before it takes root.
It should be noted that coronaviruses obtain their lipid envelop from the cells on which they bud (the cells of the host), and this envelop easily succumbs to bio-membrane disruptors.
The authors write that current research shows that the salivary glands and the throat play an important role in the replication and transmission of SARS-Cov-2 viruses. However, while the lipid membrane of these viruses can be easily destroyed, not a lot of research has been done to establish how that can be achieved.
The team suggests that attacking the lipid membrane is easy and even if the coronaviruses mutate, they will still remain vulnerable to the destruction of their lipid envelop.
The APS team also reviewed different ingredients found in approved dental mouthwash products. Those ingredients that could destroy the lipid membrane of the coronaviruses include hydrogen peroxide, ethanol, povidone-iodine, chlorhexidine and so many others.
The review team concludes that several of the mouthwash formulations have so much potential that they deserve to be subjected to clinical studies to evaluate to what extent they would be helpful in destroying the lipid envelop of coronaviruses, and thereby slowing the spread of SARS-Cov-2.
This is an interesting suggestion that could intrigue biomedical sector players like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) who would probably be interested in seeing low-cost solutions of stemming the spread of the ongoing pandemic available to the most vulnerable populations around the world.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S.…
For a long time, scientists have wondered why many individuals that have several risk factors linked to cancer development never…
Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that…
Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision…
Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately…
According to the findings of a recent poll conducted by Gallup and West Health, almost a quarter…